David Kaufman joined the Bill & Melinda Gates Medical Research Institute at its founding in 2018. He has helped establish the Gates MRI as a “nonprofit biotech,” developing novel drugs and vaccines for tuberculosis, malaria, enteric diseases, neonatal health, and other global health challenges. Previously, he led Translational Oncology at Merck Research Laboratories, where he oversaw immuno-oncology translational medicine, biomarker development and global translational research partnering. He joined Merck through the Merck Drug Development and Leadership Program, and worked across vaccines, infectious diseases and clinical oncology. He received his M.D. from Cornell University and his Ph.D. in immunology and molecular virology from The Rockefeller University.
He trained in Internal Medicine at the University of California, San Francisco and in Infectious Diseases at Massachusetts General Hospital and Brigham and Women’s Hospital. Prior to joining Merck, he was a physician in the Division of Infectious Diseases and the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and an Instructor in Medicine at Harvard Medical School, where his research focused on translational HIV vaccine development and vaccine-elicited mucosal immunity. He is a member of the Board of Directors of the Society for the Immunotherapy of Cancer and leads SITCs global access initiative for cancer immunotherapy. He is a Director of Hookipa Pharma.